8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C.  20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

September 13, 2011

	TRANSGENOMIC, INC.
	(Exact name of registrant as specified in its charter)
Delaware		000-30975	911789357
(State of Incorporation)		(Commission File Number)	(IRS Employer Identification  Number)
12325 Emmet Street, Omaha, Nebraska			68164
(Address of principal executive offices)			(Zip Code)
	(402) 452-5400
	(Registrant’s telephone number, including area code)
	Not applicable
	(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 7.01  Regulation FD Disclosure.

On September 12 and 13, 2011 registrant participated in an investment community meeting in New York, New York.  In connection with this meeting registrant gave a presentation to investors on September 13, 2011.  A copy of the presentation used in such meeting is attached as Exhibit 99.1 hereto.

The information under this Item 7.01 and in Exhibit 99.1 hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section.  The information under this Item 7.01 and Exhibit 99.1 hereto shall not be deemed incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, as amended, unless otherwise expressly indicated in such a registration statement or other document.

Item 9.01  Financial Statements and Exhibits.

(d) Exhibits

Exhibit No. Description

99.1  Investor presentation slides

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: September 16, 2011	TRANSGENOMIC, INC.
	By:	/s/ Brett L. Frevert
		Brett L. Frevert
		Chief Financial Officer

EX-99.1

Transgenomic, Inc. Rodman & Renshaw 13th Annual Healthcare Conference September 2011 Offering innovative products and services for personalized medicine (OTCBB: TBIO) 1

2 Forward - Looking Statements Certain statements in this presentation constitute “forward - looking statements” of Transgenomic within the meaning of the Private Securities Litigation Reform Act of 1995, which involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. Forward - looking statements include, but are not limited to, those with respect to management's current views and estimates of future economic circumstances, industry conditions, company performance and financial results, including the ability of the Company to grow its 4 involvement in the diagnostic products and services markets. The known risks, uncertainties and other factors affecting these forward - looking statements are described from time to time in Transgenomic's filings with the Securities and Exchange Commission. Any change in such factors, risks and uncertainties may cause the actual results, events and performance to differ materially from those referred to in such statements. Accordingly, the Company claims the protection of the safe harbor for forward - looking statements contained in the Private Securities Litigation Reform Act of 1995 with respect to all statements contained in this press release. All information in this press release is as of the date of the release and Transgenomic does not undertake any duty to update this information, including any forward - looking statements, unless required by law.

3 Advancing personalized medicine through proprietary molecular technologies and world - class clinical and research services Who We Are Transgenomic Diagnostic Tools Bioinstruments, reagents, and other bioconsumables for molecular testing and cytogenetics Transgenomic Clinical Laboratories CLIA certified reference laboratory specializing in molecular diagnostics Transgenomic Pharmacogenomic Services Contract research laboratory specializing in pharmacogenomic biomarker development and mutation discovery

Diagnostics Market • Valued Service – Diagnostics represents 2 - 3% of $2.6T healthcare spend but influences 70 - 80% decisions – Reduces downstream costs – Improves drug efficacy and reduce adverse drug effects • Genomics revolution provides unparalleled opportunity for growth within diagnostics space • Molecular diagnostics alone $7BB, projected to grow to $58BB by 2026, or 15%/year 4 Source : G - 2 Reports

Our Pathway to Market Leadership 5 Complementary businesses drive revenue , supporting i nnovation and high - value product d evelopment , building to long - term p rofitability Areas of Focus Oncology Cardiology Neurology Clinical Labs Companion Diagnostics Diagnostic Tools Pharmacogenomic Services Proprietary Technology

6 Innovation Driving Value Transgenomic’s Diagnostic Tools offer both established and cutting - edge technologies defined by their best in class sensitivity and comprehensive scanning ability for detecting mutations

Why Are Mutations Important? Many Serious Diseases Are Driven by a Change in Protein Structure

…In Cancer 8 Cancer is a Progressive Genetic Disorder Mutation Disease Progression Treatment Challenges Ultra - sensitive DNA Detection Heterogeneity of cancer demands highly sensitive mutation scanning methods for early detection of important genetic changes

» WAVE ® , SURVEYOR ® Scan, BLOCker™ - Sequencing and ICE COLD - PCR are breakthrough methodologies that enhance the ability of Sanger sequencing to detect and identify mutations at or significantly beyond the levels achieved with allele - specific probes or next generation sequencing » SURVEYOR Scan kits can be run on multiple platforms → Ability to meet any research or testing need » BLOCker - Sequencing and ICE COLD - PCR are run on standard Sanger sequencing equipment found in most molecular labs » Cost Containment: → No need for fluorescently labeled nucleotides or probes → No need to test for specific mutations Technologies with Broad Appeal 9

10 WAVE ® System High sensitivity mutation detection instrument; leading system for BRCA analysis in Europe and Asia

11 SURVEYOR ® Mutation Detection Mismatch endonuclease that identifies both presence and location of a mutation Long fragments Short fragments Uncut strand

Conventional versus COLD - PCR 12

ICE COLD - PCR I mproved and C omplete E nrichment CO amplification at L ower D enaturation temperatures – PCR • Patented enhancement to COLD - PCR demonstrating reproducible detection at very high analytic sensitivity (100 to 1000 fold over “normal” Sanger sequencing) for detection of DNA in blood and body fluids • Specifically enhances amplification of mutated DNA • Application to detection of cancer gene mutations for early diagnosis of disease, monitoring of disease, recurrence and therapeutic response • Exclusively licensed from Dana Farber for Sanger sequencing and pyrosequencing, non - exclusive for RT - PCR, next gen sequencing Several collaborations beginning to further validate ICE COLD - PCR 13

BLOCker™ - Sequencing BLOCker - Sequencing: BL ocking O ligonucleotide C ycle Sequencing • BLOCker - Sequencing is Transgenomic’s patented approach which selectively blocks the sequencing of wild - type DNA and allows samples with lower concentrations of mutant DNA to be sequenced for any mutation within a target DNA sample • Enhances the limit of detection of standard Sanger sequencing by 10 - fold • Enriches for direct sequencing of mutated DNA over wild - type (unmutated DNA) 14

15 Value of ICE COLD - PCR/ BLOCker • Combined techniques offer the highest sensitivity mutation detection capability in the marketplace • Automation and multiplex capable • Runs on standard Sanger sequencing instrumentation without any changes – Most labs worldwide already have Sanger equipment – Exceeds sensitivity of Next - Gen platforms • BLOCker can be applied to tumor testing or combined with ICE COLD - PCR to increase sensitivity • ICE COLD - PCR permits mutation testing on blood and Circulating Tumor Cells (CTC’s)

Competing Technologies 16 ICE COLD - PCR KRAS exon 2 Allelle Specific PCR TheraScreen KRAS Analytic Sensitivity 0.1% - 0.01 % 1 - 2% Instrumentation Required PCR Thermal cycler PCR Thermal cycler Sanger Sequencer RT PCR instrument Tissue Medium accepted Blood Circulating Tumor Cells Tissue Reactions per patient sample 1 7 Detect unknown sequence variants Detect deletions/insertions

17 New Products Driving Significant Value Marketed Late - Stage Development

18 Transgenomic Clinical Laboratories

19 Expanding CLIA - certified Reference Lab MITOCHONDRIAL GENOME DISORDERS MITO - WGA DFNS MITO - PT - DEL LHON MITO - DEL MELAS MITO - COPY MERRF CYTB NARP RCD NUCLEAR MITOCHONDRIAL DISORDERS NUCLEAR - MITOME POLG BCS1L POLG2 DGUOK SLC25A4 MPV17 C10orf2 TK2 AD - PEO PANEL MITO - DEP TYMP MITO - DEP/DEL COMPLEX I PANEL COMPLEX IV PANEL EPILEPSY AND SEIZURE - RELATED DISORDERS FSP SCN1A - COM FFSP SCN1B SCN1A GABRG2 SCN1A - DEL/DUP PCDH19 SCN1A - REF OTHER TESTS CPT2 MECP2 - COM OPA1 BDNF VLCAD PTEN CDKL5 UBE3A MECP2 FRAGX - M MECP2 - DEL/DUP FRAGX - F MECP2 - REF NOONAN CHROMOSOMAL ANALYSIS KARYO CMA - 180K CARDIOLOGY FAMILION LQTS FAMILION LQTS Large Deletion/Duplication FAMILION BrS FAMILION CPVT FAMILION SQTS FAMILION Timothy Syndrome FAMILION ARVC FAMILION DCM FAMILION CD - DCM FAMILION HCM FAMILION Left LVNC FAMILION Marfan/TAAD FAMILION Marfan Large Deletion/Duplication ONCOLOGY KIT PIK3CA KIT 1 P53 KIT 2 PTEN KRAS VHL Broad Molecular Testing Services For:

20 The Preeminent Inherited Cardiology Franchise Test Long QT Syndrome List Price Disease Hypertrophic Cardiomyopathy Brugada Syndrome Catecholaminergic Polymorphic Ventricular Tachycardia Arrhythmogenic Right Ventricular Cardiomyopathy $5400 $2700 $5400 $5400 $5400 Dilated Cardiomyopathy $5400 Reference: 1 Prevalence & incidence rates exclude International markets. Sources: Selected industry and academic publication s a nd resources. Greater than 60% Market Share

21 Successful Integration of CLDA Assets • Accelerates Transgenomic to ~ $32 million run rate with addition of $10.5 million in molecular lab testing sales • Brings state - of - the - art laboratory, key scientific, billing, customer service and marketing employees & expertise • Enables consolidation of company’s lab services • Brings 280 million covered lives under reference lab testing contracts • Brings biomarker development program with significant potential – Plavix assay, FC gamma assay • Purchase price $15.4 million (cash/notes), supported by Third Security (RJ Kirk, CEO)

22 Transgenomic Pharmacogenomic Services

23 Pharmacogenomic Services • Market leader in highest sensitivity DNA mutation detection for key cancer gene mutation studies employing Sanger sequencing, WAVE and SURVEYOR • ICE COLD - PCR Assays used to detect key cancer gene mutations in blood are a key future process enhancement driving growth • Also offer CGH, methylation and gene expression assays • Studies completed or on - going with top pharma companies • Pharma funding supports new assay and technology development

Strong Revenue Platform Q1 09 Q2 09 Q3 09 Q4 09 Q1 10 Q2 10 Q3 10 Q4 10 Q1 11 Q2 11 Clinical Labs Pharmacogenomic Services Diagnostic Tools 24 (Pro forma) ($ In ‘000)

25 • Founded 1997 • Global Footprint • Employees: 167 • O/S 49.2 Million • 2011 Proj. Revenue $32M • Projected Income Breakeven in 2012 • Cash into 2012 Transgenomic Today

26 Integrated Strategy for Growth • Expand consolidated reference laboratory business following successful integration of CLDA assets – Expand testing menu – License new markers – Acquire and integrate complementary businesses • Leverage mutation detection sensitivity leadership to build and market best - in - class assay panels in our Services and Tools businesses targeting key oncology genes • Continue licensing activities for panel and technology build - out • Achieve high - margin profitability through innovations that bridge drug development and areas of high unmet medical need

Transgenomic, Inc. Rodman & Renshaw 13th Annual Healthcare Conference September 2011 Offering innovative products and services for personalized medicine (OTCBB: TBIO) 27